Introduction {#S0001}
============

Multidrug-resistant Gram-negative bacteria such as carbapenem-resistant Enterobacteriaceae have led to the resurgent use of polymyxins (including polymyxin B and colistin) as "last-line" treatment options.[@CIT0001]--[@CIT0003] However, the increased use of polymyxin antibacterials has been accompanied by more frequent reports of emerging polymyxin-resistant isolates around the world.[@CIT0001],[@CIT0003],[@CIT0004] The mechanisms of polymyxin resistance have been found to involve alterations in the PmrAB or PhoPQ two-component regulatory systems caused by chromosome-mediated mutations.[@CIT0001],[@CIT0004] Although the earliest reports of the emerging plasmid-mediated colistin resistance gene *mcr*-1 originated from China, subsequent studies from other countries reported similar results.[@CIT0001],[@CIT0005]--[@CIT0007] In China, the prevalence rate of the *mcr-1* gene in Enterobacteriaceae in samples from humans ranged from 0.6% among consecutive clinical infection isolates in central China to 6.2% among fecal samples of patients in southern China.[@CIT0008],[@CIT0009] Several studies have focused on clinical *Escherichia coli* isolates carrying the *mcr-1* gene from patients with bloodstream infection.[@CIT0007],[@CIT0010],[@CIT0011] In a recent Chinese study, Quan et al showed that 1% of *E. coli* isolates causing bloodstream infections carried *mcr-1*.[@CIT0001] More worryingly, the co-presence of the *mcr-1* gene with carbapenem and extended-spectrum beta-lactamase (ESBL) resistance genes has been reported in several studies,[@CIT0001],[@CIT0005],[@CIT0011] indicating the possibility of pan-drug resistance strains. Many plasmids, such as IncHI2 and IncI2, have been involved in the spread of *mcr-1*. China's high population density makes the country vulnerable to uncontrolled spread of *mcr-1*-positive *E. coli* unless vigorous surveillance measures are implemented immediately.

The aims of this study were to investigate the prevalence and molecular characteristics of the *mcr-1* gene in *E. coli* isolates obtained from all patients with bloodstream infection over a year in a Chinese teaching hospital. The susceptibility profiles of the *mcr-1*-positive strains and the prognostic impact of this gene were also assessed.

Materials and methods {#S0002}
=====================

Bacterial isolates {#S0002-S2001}
------------------

From January to December 2016, 144 consecutive, non-repetitive *E. coli* isolates causing bloodstream infections, one from each patient, were collected at Xiangya Hospital, a general teaching hospital affiliated with Central South University (Changsha, Hunan Province, China) that has 3500 beds and 7500--10,000 patient visits every day. Isolates were identified using the Vitek 2-system (bioMérieux, Marcy-l'Étoile, France). The *mcr-1*-positive control strain was provided by Prof. Jianzhong Shen, who was the first to report the *mcr-1* gene. *E. coli* ATCC 25922 was used as a negative quality control strain.

Screening for the *mcr-1* gene in clinical strains {#S0002-S2002}
--------------------------------------------------

Screening for the *mcr-1* gene was performed as previously described.[@CIT0005] The PCR products were bidirectionally sequenced. Sequence type (ST) determination was performed according to the *E. coli* multilocus sequence typing (MLST) database.[@CIT0001] The primers used for all PCR reactions are listed in [Table S1](#ST0001).

Clinical data collection {#S0002-S2003}
------------------------

For the cases of bloodstream infection caused by *mcr-1*-positive *E. coli*, we reviewed the medical records and collected patient data, including data on demographic characteristics, underlying disease, clinical manifestations, treatments, and clinical outcomes. The study was approved by the Ethical Committee of Xiangya Hospital of Central South University.

Antimicrobial susceptibility testing {#S0002-S2004}
------------------------------------

The minimum inhibitory concentration (MIC) of colistin for the *mcr-1*-positive isolates was determined using the broth microdilution method.[@CIT0012] The antimicrobial susceptibility of other antibacterials, including ampicillin, ceftazidime, cefepime, aztreonam, piperacillin--tazobactam, imipenem, ertapenem, gentamicin, amikacin, ciprofloxacin, and trimethoprim/sulfamethoxazole, was determined using the Vitek 2 system (bioMérieux). The results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint recommendations.[@CIT0013]

Conjugation experiment {#S0002-S2005}
----------------------

The conjugation experiment was carried out in mixed broth cultures with rifampin-resistant *E. coli* EC600 as the recipient strain. Briefly, purified donor strains (*mcr-1*-positive strains) and recipient strains (*E. coli* EC600) were separately inoculated in Luria--Bertani (LB) broth at 37 °C for 4 h. A 20 µl aliquot of mixture containing 100 µl of each of the above cultures was then added onto a microporous membrane that was pre-placed on Mueller--Hinton agar. After overnight culture at 37 °C, all strains were collected and the *E. coli* transconjugants were then selected on the basis of growth on Mueller--Hinton agar containing colistin (2 mg/L) and rifampicin (600 mg/L).[@CIT0001] Transfer frequencies were calculated as the number of transconjugants obtained per recipient. The presence of *mcr-1* was confirmed by PCR. The transconjugants' colistin MIC values were also determined.

Plasmid replicon typing {#S0002-S2006}
-----------------------

Plasmid replicons were determined using the PCR-based replicon typing scheme.[@CIT0014]

Results {#S0003}
=======

Screening for the *mcr-1* gene {#S0003-S2001}
------------------------------

Among the 144 *E. coli* strains recovered from patients with bloodstream infection, three (2.1%) were positive for the *mcr-1* gene.

Antimicrobial susceptibility and molecular characteristics of *mcr-1* genes {#S0003-S2002}
---------------------------------------------------------------------------

As indicated in [Table 1](#T0002){ref-type="table"}, the *mcr-1*-positive *E. coli* strains in this study, herein designated \#1, \#2, and \#3, all exhibited an unfavorable antimicrobial susceptibility profile in addition to exhibiting colistin resistance conferred by the *mcr-1* gene. The MLST results indicated that the three isolates were assigned to three different STs: ST457, ST101, and ST1413, respectively.Table 1Antibiotic susceptibility, ST and replicon type of the three *mcr-1*-positive isolatesStrainSusceptibility categorizationSTReplicon typeCSTAMPCAZFEPATMTZPIPMETMGENAMKCIPSXT\#14 (R)2 (S)^a^\>32 (R)16 (R)2 (I)16 (R)8 (S)≤1 (S)≤0.5 (S)≤1 (S)≤2 (S)2 (R)\>16/304 (R)457I1\#24 (R)4 (R)^a^\>32 (R)16 (R)16 (R)\>64 (R)≤4 (S)≤1 (S)≤0.5 (S)\>16 (R)≤2 (S)\>4 (R)\>16/304 (R)101HI2, N\#34 (R)-^b^\>32\
(R)≤1 (S)≤1 (S)≤1 (S)≤4 (S)≤1 (S)≤0.5 (S)\>16 (R)≤2 (S)≤0.25 (S)≤1/19 (S)1413-^b^[^1][^2]

Strain \#1 carried IncI1 replicons. Strain \#2 carried IncHI2 and IncN replicons. Strain \#3 was not typed ([Table 1](#T0002){ref-type="table"}). In the conjugation experiment, the *mcr-1* gene was successfully transferred to the *E. coli* EC600 standard recipient from strains \#1 and \#2, but not from strain \#3. The transfer frequency of the *mcr-1* gene for strains \#1 and \#2 was 6.4×10^−6^ and 2.2×10^−6^, respectively. The two resulting transconjugants both exhibited elevated colistin MIC values.

Clinical information on the three patients infected with *mcr-1*-positive isolates {#S0003-S2003}
----------------------------------------------------------------------------------

The demographic and clinical characteristics of the three patients are summarized in [Table 2](#T0003){ref-type="table"}. All three patients infected with *mcr-1*-positive *E. coli* had severe underlying diseases. Two patients were hospitalized within 3 months prior to the onset of bloodstream infection. Patient \#1 was a 72-year-old woman with a history of right hemicolectomy because of colon cancer. She did not follow clinical recommendations regarding receiving postoperative chemotherapy and she was later diagnosed with colon cancer recurrence and metastasis. Patient \#2 was a 10-year-old male child. He was diagnosed with acute leukemia and had undergone chemotherapy on three occasions. He was admitted to the Emergency Department due to septic shock. Patient \#3 was a 47-year-old man with several underlying diseases, including coronary heart disease, type 2 diabetes mellitus, diabetic nephropathy, and stage 5 chronic kidney disease. After hemodialysis, he was admitted to hospital after developing signs of septic shock. All three patients with bloodstream infection were cured after treatment with antibacterials that they had been found to be susceptible to.Table 2Clinical characteristics of the three patients infected with *mcr-1*-positive isolatesClinical characteristicPatient \#1Patient \#2Patient \#3Age (years)721047GenderFMMHospital admission date06/15/201601/12/201611/29/2016Underlying diseaseColon cancerAcute leukemiaDiabetes mellitus, coronary heart disease, hypertension, chronic hepatitis B, diabetic nephropathy, stage 5 chronic kidney diseaseSurgeryRight hemicolectomyNoNoInvasive proceduresNoPeripherally inserted central catheterHemodialysisHospitalization within 3 monthsYesYesNoPrior broad-spectrum antibacterial use within 3 monthsCeftazidimeCefoperazone-sulbactamNoPrevious colistin useNoNoNoPrevious animal exposureNoNoNoSource of infectionPrimary bacteremiaPneumoniaHemodialysisAcquisition of bacteremiaHealthcare-associatedHealthcare-associatedHealthcare-associatedMaximum temperature (°C)39.240.240Antibacterial use after isolationImipenemPiperacillin--tazobactam, imipenemMeropenem, piperacillin--tazobactamTreatment duration (days)10522OutcomeSurvivedSurvivedSurvived

Discussion {#S0004}
==========

In our study, 144 clinical *E. coli* isolates were collected from patients treated for bloodstream infection in a teaching hospital in China. Of these isolates, three (2.1%) carried *mcr-1* genes. Our data showed that the low prevalence of the *mcr-1* gene among *E. coli* isolates from human bloodstream infections was slightly higher than that observed (0--1%) from patients in other countries and regions,[@CIT0001],[@CIT0011],[@CIT0015],[@CIT0016] whereas Lai et al detected *mcr-1* carriage in 75% of *E. coli* strains from pigs.[@CIT0011] Hence, the reservoir for *mcr-1*-positive *E. coli* seems to be larger among animals than among humans. Some studies have reported that *mcr-1*-positive *E. coli* might have a susceptibility profile that is generally favorable for antibacterials other than colistin.[@CIT0017],[@CIT0018] On the other hand, Lai et al have shown that *mcr-1*-positive *E. coli* can be highly resistant, thus suggesting that the potential for *mcr-1* gene dissemination is not limited to community strains with a low baseline level of antimicrobial resistance.[@CIT0011] In this study, the *mcr-1*-positive *E. coli* strains \#1 and \#2 were resistant to cephalosporins, while all three strains were susceptible to carbapenems. This highlights the risk that the *mcr-1* gene might spread even in carbapenem-susceptible *E. coli* isolates. This may be due to the fact that not all plasmids with the *mcr-1* gene carry other genes conferring resistance to clinically relevant antibacterials such as carbapenemase.[@CIT0017],[@CIT0019] Therefore, it seems imperative that testing for colistin susceptibility should be part of the clinical routine in all microbiological laboratories in China.

A recent study involving an MLST analysis reported the extreme divergence of *E coli* strains carrying *mcr-1* in different provinces and even in different hospitals in China.[@CIT0020] In the current study, the high genetic diversity among the *mcr-1*-positive *E. coli* strains \#1, \#2, and \#3, which belonged to STs ST457, ST101, and ST1413, respectively, indicates that the isolates were unrelated. *E. coli* ST101 is considered as having an environmental lineage (related to water, sewage, and poultry), while many clinical isolates in multiple countries are also classified as *E. coli* ST101.[@CIT0020]--[@CIT0022] It is also regarded as a reservoir for antibiotic resistance genes. The *mcr-1*-positive *E. coli* ST101 strains have been detected in chickens, public transportation, and one hospital in China.[@CIT0020],[@CIT0022],[@CIT0023] Thus, more attention should be focused on *E. coli* ST101 as it might promote the spread of *mcr-1*. In contrast, *mcr-1*-positive *E. coli* ST457 is very rare and we are the first to report ST1413 carrying *mcr-1* in China.

In this study, we found that strain \#1 carried one replicon (IncI1) and strain \#2 carried two replicons (IncHI2 and IncN). Several studies have reported that the *mcr-1* gene is primarily located on two prevalent plasmids (IncHI2 and IncI2).[@CIT0001],[@CIT0010],[@CIT0024]--[@CIT0026] Consequently, these plasmids might play an important role in driving the spread of the *mcr-1* gene. The conjugation experiment in this study, in which the *mcr-1* gene was successfully transferred from strains \#1 and \#2 to the *E. coli* EC600 standard recipient, clearly demonstrates the potential for horizontal transfer of the *mcr-1* gene. In contrast, in an experiment using the same methodology, strain \#3 did not transfer the gene. This indicates that the *mcr-1* gene of strain \#3 might be located on a yet unknown non-conjugative plasmid. Further studies are required to elucidate and monitor the spread of the *mcr-1* gene in China.

Previous reports on the epidemiology of *mcr-1*-positive members of the Enterobacteriaceae bacterial family have suggested a narrow variety of sources for bloodstream infection.[@CIT0007],[@CIT0017],[@CIT0018],[@CIT0027] Contrary to these findings, we have showed that *mcr-1*-positive *E. coli* might invade the bloodstream, not only from the urinary and biliary organs,[@CIT0007],[@CIT0017],[@CIT0018],[@CIT0027] but also from the respiratory tract and as primary, idiopathic infection. Some of our findings are in line with previous studies,[@CIT0007],[@CIT0017],[@CIT0018] however, since unhealthy patients might be vulnerable to *mcr-1*-positive *E. coli* bloodstream infection. Previous studies have established an association between infection and both kidney disease and diabetes mellitus,[@CIT0007],[@CIT0017],[@CIT0018] and, of the three patients in our study, two had cancer and one had diabetes mellitus. Of the three patients, two were treated with antibacterials in the 3-month period before admission to hospital. Interestingly, none of the patients received previous treatment with colistin or had close contact with farm animals. We postulate that considering the occurrence of *mcr-1*-positive Enterobacteriaceae in the environment, vegetables, and meat in China,[@CIT0028]--[@CIT0030] the patients might have been exposed to the *mcr-1* gene via these sources. Similar to previous reports,[@CIT0007],[@CIT0017],[@CIT0018],[@CIT0027] all three patients with *mcr-1*-positive *E. coli* bloodstream infection had a favorable outcome after treatment with antibacterials that they had been found to be susceptible to. However, Lai et al have reported that four patients out of ten (40%) succumbed to bloodstream infection despite being intensively treated (often with more than one antibacterial preparation).[@CIT0011] The inconsistent findings regarding the outcomes in these studies might be due to the small sample sizes.[@CIT0007],[@CIT0011],[@CIT0017],[@CIT0018],[@CIT0027]

A limitation of our study is that the *mcr-1*-positive strains were not analyzed by whole-genome sequencing and thus further studies are required to better clarify the molecular characteristics of this resistance gene. However, this systematic investigation of all bloodstream infections caused by *E. coli* over a year in a Chinese hospital is noteworthy.

Conclusion {#S0005}
==========

In an examination of 144 consecutive, non-repetitive, clinical samples of invasive *E. coli* isolates retrieved from a hospital in China over one year, we found three invasive *E. coli* isolates that were *mcr-1*-positive (2.1% of all samples). Patients, especially those with underlying diseases, may be infected with *mcr-1*-positive *E. coli* even if they have not received previous treatment with colistin. The three *mcr-1*-positive *E. coli* isolates had varied susceptibility profiles, although all three were susceptible to carbapenems. This therapeutic window is crucial given the risk of rapid deterioration in high-incidence areas of the world. We call for immediate inclusion of colistin in routine susceptibility testing in all microbiological laboratories in China.
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Supplementary material {#S0008}
======================

Table S1The primers used for all PCR reactions in this studyNameDirectionDNA sequence (5ʹ-3ʹ)*mcr-1*mcr-1-FCGGTCAGTCCGTTTGTTCmcr-1-RCTTGGTCGGTCTGTAGGGMLSTadk-FATTCTGCTTGGCGCTCCGGGadk-RCCGTCAACTTTCGCGTATTTadk-F1TCATCATCTGCACTTTCCGCadk-R1CCAGATCAGCGCGAACTTCAfumC-FTCACAGGTCGCCAGCGCTTCfumC-RGTACGCAGCGAAAAAGATTCfumC-R1TCCCGGCAGATAAGCTGTGGgyrB-FTCGGCGACACGGATGACGGCgyrB-RATCAGGCCTTCACGCGCATCgyrB-R1GTCCATGTAGGCGTTCAGGGicd-FATGGAAAGTAAAGTAGTTGTTCCGGCACAicd-RGGACGCAGCAGGATCTGTTmdh-FATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGGMdh-RTTAACGAACTCCTGCCCCAGAGCGATATCTTTCTTmdhF-1AGCGCGTTCTGTTCAAATGCmdhR-1CAGGTTCAGAACTCTCTCTGTpurA-FCGCGCTGATGAAAGAGATGApurA-RCATACGGTAAGCCACGCAGApurA-F1TCGGTAACGGTGTTGTGCTGrecA-FCGCATTCGCTTTACCCTGACCrecA-RTCGTCGAAATCTACGGACCGGArecA-F1ACCTTTGTAGCTGTACCACGrecA-R1AGCGTGAAGGTAAAACCTGTGPlasmid replicon typingB/O-FGCGGTCCGGAAAGCCAGAAAACB/O-RTCTGCGTTCCGCCAAGTTCGAFIC-FGTGAACTGGCAGATGAGGAAGGFIC-RTTCTCCTCGTCGCCAAACTAGATA/C-FGAGAACCAAAGACAAAGACCTGGAA/C-RACGACAAACCTGAATTGCCTCCTTP-FCTATGGCCCTGCAAACGCGCCAGAAAP-RTCACGCGCCAGGGCGCAGCCT-FTTGGCCTGTTTGTGCCTAAACCATT-RCGTTGATTACACTTAGCTTTGGACK/B-FGCGGTCCGGAAAGCCAGAAAACK/B-RTCTTTCACGAGCCCGCCAAAW-FCCTAAGAACAACAAAGCCCCCGW-RGGTGCGCGGCATAGAACCGTFIIA-FCTGTCGTAAGCTGATGGCFIIA-RCTCTGCCACAAACTTCAGCFIA-FCCATGCTGGTTCTAGAGAAGGTGFIA-RGTATATCCTTACTGGCTTCCGCAGFIB-FGGAGTTCTGACACACGATTTTCTGFIB-RCTCCCGTCGCTTCAGGGCATTY-FAATTCAAACAACACTGTGCAGCCTGY-RGCGAGAATGGACGATTACAAAACTTTI1-FCGAAAGCCGGACGGCAGAAI1-RTCGTCGTTCCGCCAAGTTCGTFrep-FTGATCGTTTAAGGAATTTTGFrep-RGAAGATCAGTCACACCATCCX-FAACCTTAGAGGCTATTTAAGTTGCTGATX-RTGAGAGTCAATTTTTATCTCATGTTTTAGCHI1-FGGAGCGATGGATTACTTCAGTACHI1-RTGCCGTTTCACCTCGTGAGTAN-FGTCTAACGAGCTTACCGAAGN-RGTTTCAACTCTGCCAAGTTCHI2-FTTTCTCCTGAGTCACCTGTTAACACHI2-RGGCTCACTACCGTTGTCATCCTL/M-FGGATGAAAACTATCAGCATCTGAAGL/M-RCTGCAGGGGCGATTCTTTAGG
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[^1]: **Notes:** ^a^transconjugants; ^b^not detected.

[^2]: **Abbreviations:** CST, colistin; AMP, ampicillin; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; TZP, piperacillin--tazobactam; IPM, imipenem; ETM, ertapenem; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; R, resistant; I, intermediate; S, susceptible.
